Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Case report

A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report

Authors: Hiromichi Sonoda, Tomoharu Shimizu, Eiji Mekata, Yoshihiro Endo, Mitsuaki Ishida, Tohru Tani

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Pathological complete remission of advanced stage rectal adenocarcinoma by chemotherapy alone is rare. A case of advanced stage, low-lying rectal adenocarcinoma in which a complete response to treatment was obtained with mFOLFOX6 and panitumumab (Pmab) is reported.

Case presentation

A 53-year-old man was referred to Shiga University of Medical Science hospital Shiga, Japan, complaining of bloody stool. Gastrointestinal endoscopy was performed, and advanced stage rectal adenocarcinoma was diagnosed. Computed tomography (CT) revealed regional lymph node metastases in the mesorectum. Neoadjuvant chemotherapy (NAC) with mFOLFOX6 and Pmab was planned.
Endoscopy following four courses of chemotherapy revealed that the rectal cancer had been markedly reduced, and the results of biopsies of the rectal tumor were negative for cancer. On CT, the mesorectal lymph node metastases had disappeared. Total intersphincteric resection (ISR) with a handsewn coloanal anastomosis was performed. Histological examination showed a complete response to mFOLFOX6 and Pmab in advanced stage rectal cancer.

Conclusion

The result seen in this case suggests that short-term NAC with mFOLFOX6 and Pmab was effective for low-lying rectal adenocarcinoma.
Appendix
Available only for authorised users
Literature
1.
National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Volume Version 1. 2013, Fort Washington, PA: NCCN
2.
Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012, 17 (1): 1-29. 10.1007/s10147-011-0315-2.CrossRefPubMed
3.
Nishizawa Y, Saito N, Fujii S, Ito M, Sugito M, Kobayashi A, Nishizawa Y: Association between anal function and therapeutic effect after preoperative chemoradiotherapy followed by intersphincteric resection. Dig Surg. 2012, 29 (5): 439-445. 10.1159/000345586.CrossRefPubMed
4.
Ricotta R, Vanzulli A, Moroni M, Colnago B, Oriani M, Nichelatti M, Sarnataro C, Venturini F, Di Bella S, Maiolani M, Giganti MO, Sartore-Bianchi A, Siena S: Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. Clin Colorectal Cancer. 2013, 12: 45-53. 10.1016/j.clcc.2012.07.001.CrossRefPubMed
5.
Canda AE, Terzi C, Gorken IB, Oztop I, Sokmen S, Fuzun M: Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients. Int J Colorectal Dis. 2010, 25 (2): 197-204. 10.1007/s00384-009-0807-y.CrossRefPubMed
6.
Park JS, Choi GS, Kim SH, Kim HR, Kim NK, Lee KY, Kang SB, Kim JY, Lee KY, Kim BC, Bae BN, Son GM, Lee SI, Kang H: Multicenter analysis of risk factors for anastomotic leakage after laparoscopic rectal cancer excision: the Korean laparoscopic colorectal surgery study group. Ann Surg. 2013, 257: 665-671. 10.1097/SLA.0b013e31827b8ed9.CrossRefPubMed
7.
Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, Rutten HJ, Wiggers T, Kranenbarg EK, Leer JW, Stiggelbout AM: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 1847–1858, 2005: 23-
8.
Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol. 2005, 23: 6199-6206. 10.1200/JCO.2005.14.779.CrossRefPubMed
9.
Wright JD, St Clair CM, Deutsch I, Burke WM, Gorrochurn P, Sun X, Herzog TJ: Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer. 2010, 116: 2486-2492.CrossRefPubMed
10.
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment of colon cancer. N Engl J Med. 2004, 350: 2343-2351. 10.1056/NEJMoa032709.CrossRefPubMed
11.
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004, 22: 229-237.CrossRefPubMed
12.
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004, 22: 23-30.CrossRefPubMed
13.
Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M: Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer. 2008, 98: 1204-1209. 10.1038/sj.bjc.6604297.PubMedCentralCrossRefPubMed
14.
Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I: Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI- defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010, 11: 241-248. 10.1016/S1470-2045(09)70381-X.CrossRefPubMed
15.
Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005, 23: 9243-9249. 10.1200/JCO.2005.07.740.CrossRefPubMed
16.
Beppu T, Hayashi N, Masuda T, Komori H, Horino K, Hayashi H, Okabe H, Baba Y, Kinoshita K, Akira C, Watanebe M, Takamori H, Baba H: FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res. 2010, 30: 1015-1020.PubMed
17.
Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I: A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011, 22 (9): 2042-2048. 10.1093/annonc/mdq714.CrossRefPubMed
18.
Uehara K, Ishiguro S, Sakamoto E, Maeda A, Inoue M, Tojima Y, Kobayashi S, Omiya N, Ishizuka N, Nakao A, Goto H, Nagino M: Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer. Jpn J Clin Oncol. 2011, 41 (8): 1041-1044. 10.1093/jjco/hyr084.CrossRefPubMed
19.
De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008, 19: 508-515.CrossRefPubMed
20.
Piessevaux H, Buyse M, De Roock W, Prenen H, Schlichting M, Van Cutsem E, Tejpar S: Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol. 2009, 20: 1375-1382. 10.1093/annonc/mdp011.CrossRefPubMed
21.
Li J, Rose MG, Perkal MF, Chao HH: Pathologic complete response after FOLFOX7 in a locally advanced rectal cancer. J Clin Gastroenterol. 2012, 46 (1): 87-88.CrossRefPubMed
22.
Foxtrot Collaborative Group: Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012, 13 (11): 1152-1160. 10.1016/S1470-2045(12)70348-0.PubMedCentralCrossRefPubMed
Metadata
Title
A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report
Authors
Hiromichi Sonoda
Tomoharu Shimizu
Eiji Mekata
Yoshihiro Endo
Mitsuaki Ishida
Tohru Tani
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-63

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue

Research

Curcumin inhibits proliferation of gastric cancer cells by impairing ATP-sensitive potassium channel opening

Research

Is concomitant splenectomy beneficial for the long-term survival of patients with gastric cancer undergoing curative gastrectomy? A single-institution study

Case report

Superior mediastinal paraganglioma associated with von Hippel-Lindau syndrome: report of a case

Research

Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer

Research

Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate

Research

Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study